Disease Overview：Insulinoma（INS）
Insulinoma is a rare, typically benign neuroendocrine tumor of the pancreatic beta cells that autonomously secretes excessive insulin, leading to recurrent hypoglycemia. Symptoms include neuroglycopenic manifestations—such as confusion, seizures, and loss of consciousness—as well as adrenergic symptoms like sweating, palpitations, and tremor. Diagnosis relies on biochemical confirmation (e.g., elevated insulin, C-peptide, and proinsulin levels during spontaneous or induced hypoglycemia), imaging modalities including contrast-enhanced CT/MRI, endoscopic ultrasound (EUS), and functional imaging such as 68Ga-DOTATATE PET/CT. Surgical enucleation remains the definitive treatment for localized disease, with cure rates exceeding 90% in experienced centers; medical management with diazoxide or somatostatin analogs is reserved for unresectable or metastatic cases.
China offers distinct advantages for insulinoma care: leading academic hospitals—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—host multidisciplinary endocrine-oncology teams with extensive experience in complex pancreatic neuroendocrine tumor resection and intraoperative ultrasound-guided localization. Advanced technologies—including high-resolution EUS, intraoperative fluorescence imaging, and minimally invasive robotic-assisted surgery—are widely available. Clinical outcomes align with international benchmarks: published series report >95% biochemical remission post-resection and <2% perioperative complication rates. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access for international patients—coordinating specialist consultations, arranging accredited hospital admissions, providing itemized, transparent pricing, and delivering end-to-end support from visa assistance to post-discharge follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Insulinoma (Endocrinology Department)
Non-Surgical / Medical Management
*Indicated for inoperable, metastatic, or high-surgical-risk patients; symptomatic control pending surgery.*
- •Diazoxide (50–150 mg/day): First-line medical therapy. ¥120–¥280/month ($17–$40)
- •Octreotide LAR (20–30 mg IM q4w): For diazoxide-refractory cases. ¥4,200–¥5,600/dose ($590–$790)
- •Everolimus (10 mg/day): Reserved for malignant insulinoma with mTOR pathway activation. ¥6,800–¥8,400/month ($960–$1,190)
- •*Required monitoring*: Fasting glucose (¥15), C-peptide (¥45), proinsulin (¥65), CT/MRI pancreas (¥850–¥1,200), chromogranin A (¥180), 72-hr supervised fast (¥320). Total baseline workup: ¥1,500–¥2,100 ($210–$300)
Surgical / Interventional Options
*Curative intent for localized, resectable insulinoma (≥90% of cases); performed by endocrine surgery team.*
- •Eligibility: Confirmed biochemical diagnosis + imaging-localized solitary tumor (<4 cm), no distant metastasis, ECOG PS ≤2.
- •Laparoscopic enucleation (gold standard): ¥28,000–¥36,000 ($3,950–$5,080)
- •Open distal pancreatectomy (for deep/tail lesions or suspected malignancy): ¥42,000–¥54,000 ($5,920–$7,620)
- •*Preoperative workup*: Endoscopic ultrasound (EUS) with fine-needle aspiration (¥2,400), intraoperative ultrasound (¥1,800), arterial calcium stimulation test (CST) if EUS-negative (¥3,600). Total preop: ¥7,800–¥9,200 ($1,100–$1,300)
Special / Complex Condition Management
- •Malignant insulinoma (liver metastases): Liver-directed therapy (TACE or radioembolization) ¥22,000–¥38,000 ($3,100–$5,360) per session; peptide receptor radionuclide therapy (¹⁷⁷Lu-DOTATATE) ¥85,000–¥110,000 ($12,000–$15,500) per cycle (2–4 cycles).
- •Refractory hypoglycemia pre-op: Continuous glucose monitoring (CGM) system rental + nursing supervision ¥1,200/week ($170).
Quick Selection Guide
- •Young, fit, localized tumor: Laparoscopic enucleation — optimal cure rate (>95%), lowest complication risk, fastest recovery.
- •Elderly (>75) or severe comorbidities (e.g., NYHA III CHF, COPD GOLD IV): Diazoxide + frequent small meals; avoid surgery unless life-threatening hypoglycemia.
- •Metastatic disease: Everolimus + octreotide LAR ± liver-directed therapy; prioritize symptom control and quality of life.
- •Budget-constrained (<$2,000 USD): Medical management (diazoxide + strict dietary regimen) + outpatient monitoring; defer surgery until financial readiness.
- •Rapidly progressive hypoglycemia unresponsive to meds: Urgent surgical evaluation — delay increases seizure/stroke risk; preop costs covered under critical pathway insurance reimbursement.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Insulinoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Insulinoma treatment with China top medical destinations:
